secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2021-10-01T23:59:59+00:00
Accession:  0001493152-21-024376
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics stockholders approve classified board structure; directors re-elected
--------------------------------------------------------------------------------

- At Sep 29 annual meeting, all six director nominees elected with votes ranging from 8.37M to 8.88M for each.
- Stockholders approved classified board amendment (8.82M for, 150.9K against); filed with Delaware on Oct 1, 2021.
- Board classified into three classes: Class I (Buell, Stein) term expiring 2022, Class II (Barrage, Silverman) 2023, Class III (Armen, Corvese) 2024.
- MaloneBailey LLP ratified as independent auditor for FY2021 (10.60M for, 2.8K against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315221024376/0001493152-21-024376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315221024376/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-21-024376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer